Rchr
J-GLOBAL ID：202001013762942799
Update date: Aug. 17, 2024
Shirakawa Yuki
シラカワ ユウキ | Shirakawa Yuki
Affiliation and department：
Research field (6)：
Clinical pharmacy
, Pathobiochemistry
, Immunology
, Allergies and connective tissue disease
, Tumor biology
, Neurosurgery
Research theme for competitive and other funds (2)：
- 2022 - 2025 22K
- 2022 - 2023 アトピー疾患研究センター研究費(*学内研究費)
Papers (6)：
-
Ayumi Kanemaru, Yuki Ito, Michiko Yamaoka, Yuki Shirakawa, Kou Yonemaru, Shunsuke Miyake, Misaki Ando, Masako Ota, Takeshi Masuda, Akitake Mukasa, et al. Wnt/β-catenin signaling is a novel therapeutic target for tumor suppressor CYLD-silenced glioblastoma cells. Oncology Reports. 2023. 50. 5
-
Ryo Hatano, Takumi Itoh, Haruna Otsuka, Harumi Saeki, Ayako Yamamoto, Dan Song, Yuki Shirakawa, Satoshi Iyama, Tsutomu Sato, Noriaki Iwao, et al. Humanized anti-IL-26 monoclonal antibody as a novel targeted therapy for chronic graft-versus-host disease. American Journal of Transplantation. 2022. 22. 12. 2804-2820
-
Takuichiro Hide, Ichiyo Shibahara, Madoka Inukai, Ryota Shigeeda, Yuki Shirakawa, Hirofumi Jono, Naoki Shinojima, Akitake Mukasa, Toshihiro Kumabe. Ribosomal proteins induce stem cell-like characteristics in glioma cells as an “extra-ribosomal function”. Brain Tumor Pathology. 2022. 39. 2. 51-56
-
Yuki Shirakawa, Kunimasa Ohta, Shunsuke Miyake, Ayumi Kanemaru, Akari Kuwano, Kou Yonemaru, Shota Uchino, Michiko Yamaoka, Yuki Ito, Naofumi Ito, et al. Glioma Cells Acquire Stem-like Characters by Extrinsic Ribosome Stimuli. Cells. 2021. 10. 11. 2970-2970
-
Takumi Itoh, Ryo Hatano, Yoshiya Horimoto, Taketo Yamada, Dan Song, Haruna Otsuka, Yuki Shirakawa, Shuji Mastuoka, Noriaki Iwao, Thomas M. Aune, et al. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells. Cell Death & Disease. 2021. 12. 6
ｍore...
MISC (2)：
-
秀 拓一郎, 白川 裕貴, 城野 博史, 柴原 一陽, 犬飼 円, 篠島 直樹, 武笠 晃丈, 隈部 俊宏. 脳腫瘍研究のcutting edge-先端画像、実験/分子病理、デジタル病理- 外因性リボゾームは膠芽腫細胞の可塑性や幹細胞性に関与する. Brain Tumor Pathology. 2022. 39. Suppl. 071-071
-
Takuichiro Hide, Yuki Shirakawa, Hirofumi Jono, Ichiyo Shibahara, Madoka Inukai, Naoki Shinojima, Akitake Mukasa, Toshihiro Kumabe. Intercellular communication at glioblastoma stem cell niches. Neuro-Oncology Advances. 2020. 2. Supplement_3. ii4-ii4
Lectures and oral presentations (18)：
-
リボソームの新機軸・リプログラミング能に着目した膠芽腫がん幹細胞発生メカニズムの解明
(第33回 日本癌病態治療研究会 2024)
-
IL-26 facilitates cartilage destruction and infiltration of inflammatory cells into synovium in a collagen induced arthritis model
(2022)
-
外因性リボゾームによる膠芽腫がん幹細胞様細胞の発生メカニズムの解明
(第 96 回 日本薬理学会年会 2022)
-
Novel roles of ribosomal protein S6 promotes in development and maintenance of glioblastoma multiforme stem cells
(2022)
-
リン酸化プロテオミクスを活用した CYLD 発現低下・予後不良膠芽腫に対する新規治療標的の探索
(第 74 回 日本薬理学会西南部会 2021)
ｍore...
Works (2)：
-
リボゾームタンパクに着目した膠芽腫がん幹細胞様細胞の発生メカニズム解明
-
がん幹細胞様細胞に着目した膠芽腫の病態解析
Education (1)：
- 2016 - 2020 Kumamoto University Graduate School of Pharmaceutical Sciences
Professional career (1)：
- Doctor of Pharmacy (Kumamoto University)
Work history (3)：
- 2023/04 - 現在 日本全薬工業株式会社
- 2020 - 現在 Juntendo University Faculty of medicine Department of Therapy Development and Innovation for Immune Disorders and Cancers
- 2016/04 - 2020/03 Kumamoto University Department of Clinical Pharmaceutical Sciences
Awards (3)：
- 2022/03 - 研究助成 令和4年度 熊薬研究助成会助成金
- 2019/08 - Next Generation Drug Discovery Researcher Training School Poster Society Poster Award
- 2018/09 - Young investigators symposium on clinical pharmaceutical science (YCPS) 2018 Best Presentation Award
Association Membership(s) (2)：
Japanese Society for Immunology
, 日本薬学会
